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The  class  II  antigens  of the  major  histocompatibility  complex  (MHC) 1 are 
critical to the generation of an immune response. They control the magnitude 
of the immune response of antigens and direct interactions among immunocom- 
petent cells. Despite their well-documented role in a variety of immune phenom- 
ena,  the biochemical mechanisms  of Ia-mediated  immune  effects is not clearly 
understood at this time. Biochemical analyses indicate that Ia antigens consist of 
a 33-35 kD a  chain glycoprotein and a 25-27 kD/3 chain glycoprotein, both of 
which  are  encoded  by  genes  within  the  MHC.  Over  the  past  several  years, 
additional components have been found to be noncovalently associated with the 
Ia heterodimer. The most extensively characterized of these is a 31 kD glycopro- 
tein,  termed  invariant  chain  (Ii),  which  specifically associates with  cytoplasmic 
forms of murine  Ia antigens (1).  Molecules homologous to invariant chain have 
since been identified in association with the human,  rat, and guinea pig class II 
antigens  (2-5).  Although  studied extensively by a  number of laboratories,  the 
function of the invariant chain in the biology of Ia has eluded investigators. 
In our studies of the biochemistry of MHC class II antigens, we have identified 
an  additional  molecule associated with  the  Ia  heterodimer  (6-9).  Biochemical 
studies  demonstrated  this  molecule  to  be  a  chondroitin  sulfate  proteoglycan 
(CPSG)  that  has  an  apparent  molecular  weight  of 46,000-70,000  (46-70  K) 
when analyzed by SDS-PAGE. This CSPG has been isolated from both murine 
and human  lymphoid tissue and appears to be uniquely associated with class II 
antigens and not other lymphoid cell molecules. The class II-associated CSPG is 
considerably  smaller  than  proteoglycans  that  have  been  isolated  from  other 
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tissues (10,  11) and  its specific physical association  with a  particular  membrane 
glycoprotein is an unusual feature. 
To elucidate the possible functional significance of the CSPG in the biology of 
Ia antigens, we have pursued further biochemical analyses of this molecule, The 
goal of the studies described in this report was to obtain information on the core 
protein of the CSPG. We were particularly interested in whether the core protein 
was structurally related to ~,/3, or invariant glycoproteins. We present evidence 
indicating that the core protein of the Mr 46-70  K  CSPG isolated from murine 
spleen cells is an alternately processed form of invariant chain. 
Materials and  Methods 
Radiolabeling  and Isolation  of the CSPG and its Core Protein.  B I 0.A spleen ceils  were 
labeled at a density of 1 x  107 cell/ml for 9-10 h in Duibecco's modified Eagle's medium, 
lacking methionine, and supplemented with  10% dialyzed fetal calf serum (FCS),  10 mM 
Hepes, 1 M glutamine, 5 ×  10 -5 M 2-mercaptoethanol, and [35S]methionine (1,000-1,400 
Ci/mM; Amersham Corp., Arlington Heights, IL) at 250-500 #Ci/ml. After labeling, cell 
pellets were solubilized in 0.5% Nonidet P-40 (NP-40) containing the protease inhibitors 
phenylmethylsulfonyl  fluoride  (200  #g/ml),  L-l-tosylamide-2-phenylethyl-chloromethyl 
ketone  (TPCK)  (50  #g/ml),  and  N-a-p-tosyl-L-lysine chloromethyl  ketone  (50  #g/ml) 
(Sigma Chemical Co.,  St.  Louis,  MO).  The detergent  lysates were  ultracentrifuged  at 
100,000 g for 60 min, and the soluble supernatant was pretreated as previously described 
(6), and then reacted with anti-I-A  k (10-2.16), anti-Ii (In-l), or control anti-I-A  a (MKD6) 
monoclonal antibodies. The antigen-antibody complexes were isolated with Staphylococcus 
aureus,  Cowan  I  strain  (SacI)  or  rabbit  anti-rat  immunoglobulin/SaCI  (RARIg-SaCI) 
immunoadsorbants (6).  Antibody and radiolabeled molecules were eluted from the SaCI 
pellets by incubations  in  0.5  ml of 8  M  urea,  0.05  M  sodium acetate,  0.15  M  sodium 
chloride, and 0.5% Triton X-100, pH 6 (dissociative DEAE starting buffer). After 16 h 
at 25 °C, particulate material was removed by centrifugation and the soluble supernatant 
was applied  batchwise  to  the  anion  exchange  resin  DEAE-Sephacel  (Pharmacia,  Inc., 
Piscataway, NJ), at a ratio of 0.1  ml packed Sephacel per 2.0 x  10 7 cell equivalents. After 
incubation for 2 min at 30 °C, the unbound (CSPG-depleted) material was collected and 
diluted  1:1  with  deionized  water.  The  DEAE-Sephacel  was washed twice with  5.0  ml 
dissociative DEAE starting buffer and twice with 5.0 ml of DEAE starting buffer without 
urea. CSPG-enriched material remaining bound to the resin was eluted by incubation of 
the resin with 0.5 ml of 0.8 M NaCi in 0.05 M sodium acetate and 0.002% Triton X-100, 
pH 6.0. Radioactivity in the unbound and the eluted fractions was determined, and each 
sample was dialyzed against a  200-fold excess of 0.005  M Tris-HCl, pH 7.6 for 12  h at 
4°C,  then  for an additional  6  h  against  fresh  buffer. The dialyzed samples were then 
lyophilized to dryness. The dried unbound fractions were dissolved in 0.5 ml of deionized 
water and proteins were precipitated by the addition of 3 vol of 95% ethanol containing 
1.3% potassium acetate (12).  Carrier protein (bovine serum albumin [BSA],  ovalbumin 
[OVA], bovine gamma globulin [BGG] and cytochrome c [Cyt c]) (Sigma Chemical Co.) 
was included at a total final concentration of 1.2 mg/ml. The eluted fractions from DEAE- 
Sephacel were resuspended in 0.1  ml deionized water containing 300 #g/ml each of BSA, 
OVA, and IgG and 500 #g/ml of Cyt c, and divided into two equal aliquots. One aliquot 
was treated with  chondroitinase  AC (Miles Laboratories, Inc., Elkhart,  IN) (1.5  U/ml) 
and  the  other  was  mock  digested.  In  some  experiments,  chondroitinase  ABC  (Miles 
Laboratories, Inc.) was used (see Results). Samples were incubated at 37°C for 2 h and 
then frozen at -20°C. For analytical or preparative SDS-PAGE (sodium dodecyi sulfate- 
polyacrylamide gel electrophoresis), all samples were adjusted to 0.062 M Tris, 2.0% SDS, 
2% 2-mercaptoethanol,  10% glycerol, and 0.001% phenol red, and then boiled for 2.5 
rain. 
Radiolabeling  oflnvariant Chain.  Invariant chain glycoprotein was labeled with [~H]- 1918  Ia-ASSOCIATED  CSPG CORE  PROTEIN  IS  INVAR1ANT  CHAIN 
methionine.  Labeling  was  performed  as  for  [35S]methionine  (see  above)  except  that 
[3H]methionine (85 Ci]mM; New England Nuclear, Boston, MA) was used at 200/~Ci/ml 
in  the  labeling  medium.  The  invariant  chain  was  immunoprecipitated  with  the  In-1 
monoclonal antibody (mAb), and the 31 kD species was isolated by preparative 11% SDS- 
PAGE and eluted. 
V8 Protease Peptide Mapping of [3"~S]Methionine-labeled Core Protein.  V8 peptide map- 
ping (13) was used to determine if the core protein of the CSPG had any relationship to 
the c~, ~3, or Ii chain glycoproteins. Samples containing ~,/3, and invariant chains (unfrac- 
tionated  immunoprecipitates) and  samples containing  the  purified core  protein  of the 
CSPG (prepared as detailed above) were electrophoresed separately in the first dimension 
using a modified Laemmli-Maizel discontinuous SDS]I 0% PAGE system (14,  15) in 5 × 
120  mm cylindrical gels. The cylindrical  gels were then  embedded into the top of the 
second dimension slab gel,  using  1.0%  low melting point agarose containing  75  ~g/ml 
Staphylococcal aureus  V8 protease (Miles  Laboratories, Inc.). A modified phosphate-urea 
gel system (16) was used for the second dimension gels. 
The separation gel contained 0.035  M  Na~HPO4, 0.0152  M  NaH~PO4, pH 7.1, 6  M 
urea,  15% acrylamide/bis-acrylamide (37.5:1),  0.1% SDS, 0.02% ammonium persulfate, 
and 0.05% N,N,N',N'-tetramethylethylenediamine  (TEMED). The stacking gel contained 
0.035  M Na2HPO4, 0.152  M NaH2PO4, 4.0% acrylamide/bis-acrylamide (37.5:1),  0.1% 
SDS, 0.02% ammonium persulfate, and 0.18% TEMED. The upper electrode buffer (-) 
was 0.1  M cacodylic acid, 0.1%  SDS, pH 6.0. The lower electrode buffer (+) was 0.035 
M NagHPO4, 0.015 M NaH~PO4, pH 7.1. Samples were electrophoresed using constant 
current, at 30 mA per slab gel through the stacking gel at 25°C and at 80 mA per slab 
get through the separating gel at 4°C. 
Comparative  Tryptic Peptide Mapping  of Conventional  Invariant  Chain  and  CSPG Core 
Protein  by HPLC.  Trypsin digestion  was performed as previously described (17)  with 
some modifications. In brief, lyophilized samples containing purified invariant chain or 
purified CSPG core protein were resolubilized in 2.0 ml 0.4 M Tris CI, pH 8.2 containing 
2% SDS and 100 t~g BGG, and were reduced and alkylated. The protein was precipitated 
with 20% TCA, and the precipitates were washed with ethanol/ether (1:1)  and ether to 
remove the  TCA  and  SDS.  The  precipitates  were  resolubilized  in  0.5  ml  of 0.1  M 
NH4HCO3, pH 8.2, and 0.1  ml TPCK-trypsin (200/ag/ml in 0.001  N HCI) (Worthington 
Biochemical Corp., Freehold, NJ) was added. The mixture was incubated for 30 min at 
37°C, at which time 10 #1 of 0.4 M NH4HCO3, pH 8.2 was added and an additional 0.1 
ml TPCK-trypsin, and the incubation was continued for 7 h. The reaction was stopped 
by the addition of 0.1  ml 0.8 N acetic acid, and the samples were lyophilized. The samples 
were solubilized in  0.1%  trifluoracetic acid (TFA) (Pierce Chemical Co.,  Rockford, IL) 
and chromatographed on a  C-18 reverse phase column (Vydac, Hesperia, CA) using a 
gradient (see Results) of 0-50% acetonitrile (J. T. Baker Chemical Co., Phillipsburg, NJ) 
in  0.1%  TFA and a  high  performance liquid chromatography (HPLC) system (Waters 
Associates, Milford, MA). 
Reprecipitation of  Pur~ed [~sS]Methionine-labeled CSPG.  [35S]methionine labeled CSPG 
was isolated by immunoprecipitation with either anti-I-A  k and SaCI or anti-Ii antibodies 
and  RARIg-SaCI. The  soluble  components of the  immunoprecipitates were eluted  in 
dissociative DEAE starting buffer and applied batchwise to DEAE-Sephacel. The unbound 
fraction was removed and a 0.2  M NaCI, 8 M urea wash of the ion exchange resin was 
done before elution of the CSPG from the resin by 0.8 M NaCI in 8 M urea. After elution 
from the resin, the 0.8  M  NaCl eluate was diluted to 0.2  M  NaCI, 8  M  urea and then 
reapplied to fresh DEAE-Sephacel equilibrated in 0.2 M NaC1, 8 M urea. The resin was 
again washed, first with 0.2 M NaCI in 8 M urea and then with 0.2 M NaCI before elution 
with  0.8  M  NaCI.  The  0.8  M  NaCI  eluates  from  the  second  cycle  of ion  exchange 
purification were dialyzed against 0.005 M Tris, pH 7.6, dried, and solubilized in 0.5 ml 
of deionized water containing 300 #g/ml BSA,  150 #g/ml OVA, 300 tzg/ml chondroitin 
sulfate (CS), and 300 ug/ml Cyt c. Half of each preparation was digested with chondroiti- 
nase ABC at a final concentration of 1.5 U/ml for 45 min at 37°C. After digestion, 0.05 SANT ET  AL.  1919 
ml aliquots of the untreated and chondroitinase-treated samples were added to 0.2 ml of 
phosphate-buffered saline with 0.25% NP-40 (PSN) containing  200 ~g/ml hemoglobin, 2 
mg/ml BSA, 2 mg/ml OVA, and 500 ~g/ml CS (buffer A). The samples were pretreated 
with SaCI  to reduce nonspecific  binding in subsequent experimental immunoprecipita- 
tions. Reprecipitation of each sample was attempted by incubating an aliquot of the sample 
overnight at 4°C with the antibodies indicated in Results.  Antigen-antibody  complexes 
were isolated  with  SaCI  (mouse mAb) or RARIg-SaCI  (rat  mAb)  immunoadsorbants. 
Before use in  this experiment,  the SaCI  was washed three times  in buffer A, and was 
preincubated in PSN containing  1% FCS and 500 gg/ml CS. The second-step  immuno- 
precipitates were washed  twice in buffer A, twice in PSN alone, and then analyzed  by 
SDS-PAGE.  From each preparation  used for the attempted reprecipitation,  an aliquot 
containing  radioactivity  equivalent  to  the  input  used  in  the  immunoprecipitate  was 
adjusted to 0.062 M Tris, 2.0% SDS, 2.0% 2-mercaptoethanol, 10% glycerol, and 0.001% 
phenol red, and analyzed by SDS-PAGE in parallel with the second-step  immunoprecipi- 
tates. 
Results 
Metabolic Labeling  and Purification  of the Core Protein.  The  general  strategy 
for  biochemical  analysis  of the  core  protein  of the  CSPG  was first  to  isolate 
immune  complexes bearing  Ia and  invariant  glycoproteins with  the associated 
CSPG and then to solubilize the complexes using a buffer that would dissociate 
the CSPG from the a,/3,  and invariant  chain glycoproteins.  After dissociation, 
the CSPG was physically separated from the proteins and glycoproteins by ion 
exchange  chromatography  so that  it could be analyzed independently of these 
other components. The core protein of the CSPG was then isolated by treatment 
of the proteolygcan with a glycosidase to degrade and release the glycosamino- 
glycan component. 
Thus,  B10.A spleen cells were biosynthetically labeled with [3~S]methionine, 
and  anti-la  and  anti-invariant  chain  immunoprecipitates  were prepared  from 
detergent lysates of the labeled cells. Soluble components from the SaCI-bound 
immunoprecipitates were eluted in dissociative DEAE starting buffer and applied 
batchwise to DEAE-Sephacel.  Unbound material  containing a,/3, and invariant 
chains  was  collected,  and  the  CSPG  bound  to  the  anion  exchange  resin  was 
recovered by elution with 0.8 M NaCI. The samples were analyzed, concentrated 
by lyophilization, and divided into two aliquots. One aliquot was treated with the 
glycosidase chondroitinase ABC, and the other was mock digested. Both samples 
were then analyzed by SDS-PAGE. 
Fig.  1  shows  that  [35S]methionine-labeled  a,  /3,  and  invariant  proteins  are 
clearly detectable in the unfractionated samples (lanes 3 and 4) and the DEAE- 
unbound fractions (lanes 7 and 8).  In contrast,  that fraction of the [35S]methio- 
nine-labeled immunoprecipitates  which bound to the DEAE-Sephacel consisted 
almost exclusively of the Mr 46-70  K  CSPG molecule (lanes  11  and  12).  The 
amount of radioactivity associated with the Mr 46-70 K component corresponds 
to  ~2-4%  of the  total  amount  of labeled material  in  the  immunoprecipitates, 
demonstrating  the  degree  of  purification  achieved  using  the  ion  exchange 
procedure. 
The SDS gel mobility of the DEAE-bound samples changed dramatically after 
chondroitinase  treatment.  There  was no detectable radioactive material  in the 1920  Ia-ASSOCIATED  CSPG  CORE  PROTEIN  IS  INVARIANT  CHAIN 
FIGURE  1.  SDS-PAGE analysis of immunoprecipitates fractionated by dissociative ion  ex- 
change chromatography of immunoprecipitates. B10.A spleen cells were labeled with [ssS]- 
methionine for  10  h, and immunoprecipitates were prepared  from the detergent lysates of 
labeled cells. 5% of each precipitate was reserved for analysis of unfractionated material (total) 
and the remaining 95% of each immunoprecipitate was fractionated under dissociative con- 
ditions on DEAE-Sephacel.  5% of the DEAE-unbound material was precipitated with  3  vol 
ethanol. DEAE-bound material was recovered by elution with 0.8 M NaCl (0.8 M eluate). Half 
of  the  0.8  M  NaCI  eluate  was  treated  with  chondroitinase ABC  (+CHase)  and  half was 
untreated (-CHase).  The antibodies used for immunoprecipitation were: anti-l-A  a, used as a 
negative control (lanes 2,  6,  10, and 14), anti-l-A  k (3,  7,  11, and 15), and anti-Ii (4, 8,  12, and 
16). Lanes 1, 5, 9, and 13 represent a 3~SOa-labeled anti-li immunoprecipitate used as a positive 
control for the ion exchange purification and the chondroitinase digestion. 
M,- 46-70 K region of the gel, confirming that the methionine-labeled molecule 
bore chondroitin sulfate glycosaminoglycans. Two lower molecular weight bands, 
migrating  at  Mr  38  and  28  K,  were  detected  (Fig.  1,  lanes  15  and  16).  The 
finding that there were two protein bands generated after chondroitinase diges- 
tion  of the  M,.  46-70  K  proteoglycan  suggested  that  the  Ia-associated  CSPG 
either has two distinct core proteins or that the lower molecular weight protein 
is a partial degradation  product of the 38 K species. 
To determine if the Mr 38 and 28 K molecules are structurally related to each 
other,  and  also to investigate  any structural  similarities  between the core pro- 
tein(s) of the CSPG and the t~,/3, and invariant chain glycoproteins, we compared 
peptides generated by S.  aureus  V8 protease digestion (Cleveland analysis) (13). 
Anti-Ia  and  anti-Ii  immunoprecipitates  were  prepared  from  [~5S]methionine- 
labeled  B10.A  spleen  cells.  10%  of each  precipitate  was  reserved  for  direct 
analysis of the o~, ~, and invariant glycoproteins. The remainder of each precip- 
itate  was  fractionated  on  DEAE-Sephacel  under  dissociative conditions  as de- 
scribed in the preceding section, and the eluates from the column were treated 
with  chondroitinase  ABC  to  prepare  the  core  protein.  The  unfractionated SANT  ET  AL.  1921 
FIGURE 2.  One-dimensional SDS-PAGE  analysis  of CSPG core protein and ct, 3, and invariant 
chain. Anti-I-A and anti-Ii immunoprecipitates  were prepared from NP-40 detergent lysates 
of B10.A spleen cells. 10% of the immunoprecipitates  were reserved for analysis of unfrac- 
tionated material (Total) and 90% of the immunoprecipitates were fractionated by dissociative 
ion exchange chromatography on DEAE-Sephacel. Material that bound to the resin was eluted 
with 0.8 M NaC1 (0.8 M Eluate) and was either left untreated (-CHase) or first treated with 
chondroitinase ABC (+CHase) and analyzed by one-dimensional SDS-PAGE. (Lanes 1 and 5): 
[3~S]sulfate-labeled anti-li immunoprecipitate;  (2, 6, and 8) [aSS]methionine-labeled  anti-I-A  k 
immunoprecipitate;a5  . (4,. 7, and 9) [sSS]methionine-labeled  anti-h"  " Immunoprecipitated." Lane 3 
contains  [  S]meth,omne-labeled  anti-I-E-immunoprecipitated  products  but  there  was  not 
sufficient radioactive  material  recovered from the eluted  fractions  of DEAE-Sephacel for 
further analysis. 
immunoprecipitates and the chondroitinase-treated proteoglycan were then elec- 
trophoresed by SDS-10%  PAGE.  20%  of each sample was analyzed by slab gel 
electrophoresis,  and the  remainder  of each sample was electrophoresed  in  rod 
gels for subsequent V8 digestion. 
The  V8  peptides  of the  ct,  3,  and  invariant  proteins  in  the  unfractionated 
immunoprecipitate were directly compared with those of the core protein of the 
CSPG by analysis on a  single slab gel. The two rod gel segments to be compared 
were embedded side by side on top of the stacking gel in  1% agarose containing 
V8  protease,  and  the  chon.droitinase-digested  core  protein(s)  and  the  conven- 
tional Ia/Ii glycoproteins were subjected to Cleveland analysis (13) as outlined in 
Materials and Methods.  The V8 peptides were then  electrophoresed through a 
15% acrylamide gel using a  modified phosphate buffer system. 
Autoradiographs  of the  analytical  slab  gel  and  the  two-dimensional  gels  are 
shown  in  Figs.  2  and  3,  respectively.  Examination  of the  one-dimensional  slab 1922  Ia-ASSOCIATED  CSPG CORE  PROTEIN  IS  INVARIANT CHAIN 
FIGURE 3.  Two-dimensional V8 peptide map comparison of the CSPG core protein and a, 
/3, and invariant chain glycoproteins. Unfractionated  immunoprecipitates and chondroitinase- 
treated 0.8 M NaCI eluates from the I-A and Ii preparations  (Fig. 2) were subjected to two- 
dimensional V8 protease peptide mapping (Cleveland analysis). Shown are the autoradiographs 
of the second dimension gels. One-dimensional SDS gel profiles are shown above (I-A) or 
below (Ii) autoradiographs  of the second dimension gels containing the V8 peptides. 
gel (Fig.  2) indicated  that chondroitinase  digestion  of the 0.8  M  eluates of each 
immunoprecipitate yielded two methionine-labeled proteins that migrated at Mr 
38 and 28 K, a  result similar to that obtained in the previous experiment.  Fig.  3 
shows the second-dimension  slab gels containing the V8 peptides from the anti- 
I-A and anti-Ii immunoprecipitates.  The unfractionated immunoprecipitates are 
shown  at  the  left  and  the  core  protein  of the  CSPG  at  the  right.  The  one- 
dimensional  SDS gel profile from each preparation  is also shown,  to aid  identi- 
fication  of the  proteins  in  the  V8  digest.  Bands  corresponding  to  the  ~,  13, 
invariant chains,  the  invariant  chain-related  "p25" protein,  and  the Mr  38  and 
28 K  core proteins, are indicated. SANT ET  AL.  1923 
Several observations can be made from this comparative analysis. First, the V8 
peptides of the CSPG core proteins precipitated by the I-A-specific and invariant 
chain-specific reagents were indistinguishable  from one another  (compare the 
upper and lower right-hand panels of Fig. 3). This indicates that the same CSPG 
is  isolated  with  both  these  reagents.  Second,  the  Mr  38  and  28  K  proteins 
obtained  after  chondroitinase  digestion  are  structurally  similar  to each  other. 
Two major peptides were generated  by V8 digestion  of each protein,  and the 
relative mobilities of the corresponding peptides of the Mr 38 and 28 K proteins 
were the same. This finding suggests that the 28 K protein may be a proteolytic 
product of the 38 K molecule. Finally, and most significantly, when we compared 
the peptides generated from conventional  Ia/Ii glycoproteins with those gener- 
ated from the CSPG core protein (compare left and right panels, Fig. 3), a great 
deal of similarity was seen between the peptide patterns  of the invariant  chain 
and  the  core  protein.  Two or  three  discrete  peptides  were  generated  by V8 
digestion from both the invariant chain and the core protein (brackets, Fig.  3). 
Both the intact Mr 38 K core molecule and its V8 peptides migrated as relatively 
higher molecular weight species than the invariant chain and its peptides. These 
molecular weight differences are most likely attributable to residual carbohydrate 
moieties on the core protein.  Chondroitinase  digestion of proteoglycans leaves 
at least the internal  trisaccharide xylose-galactose-galactose on the core protein. 
The diffuse gel mobilities of both the Mr 38 and 28 K species are consistent with 
the presence of variable quantities of residual carbohydrate on the core protein. 
The finding that the CSPG core protein and  the invariant  chain were struc- 
turally similar prompted us to explore whether the two molecules might also be 
antigenically  related.  An experiment  was therefore performed to determine  if 
the CSPG bears the antigenic  determinant  recognized by the monocional anti- 
invariant antibody,  In-1.  35SO4-1abeled  CSPG was separated from the Ia and  Ii 
glycoproteins  by  dissociative  ion  exchange  chromatography.  Aliquots  of this 
isolated  CSPG  were  reacted  with  control,  anti-I-A k or  anti-Ii  antibodies,  and 
putative antigen-antibody  complexes were isolated with  SaCI or  RARIg-SaCI. 
Material remaining in the supernatant of the control (anti-I-A d) immunoprecipi- 
tate  was  reacted  with  a  control  rat  antibody,  and  material  remaining  in  the 
supernatant of the anti-I-A k immunoprecipitate was reacted with anti-Ii antibody. 
The  results are  shown  in  Fig.  4.  The  CSPG was not isolated in  the antM-A  d, 
anti-I-A k, or control rat antibody immunoprecipitates (Fig. 4, lanes 2,  3,  and 5, 
respectively),  but  was isolated  in  the  anti-invariant  chain  immunoprecipitates 
(lanes 4 and 6), indicating that the CSPG indeed reacts directly with this antibody. 
The  experiments  shown  in  Fig.  4  suggested  that  the  Ia-associated  CSPG is 
antigenically realted to invariant chain. However, a complication in the interpre- 
tation  of these  experiments  was  that  the  CSPG  preparation  may  have  been 
contaminated with small amounts of the Mr 31  K invariant protein, which could 
potentially reassociate with the CSPG after removal of urea from the samples. 
This reassociation might have been responsible for the reisolation of the CSPG 
in anti-Ii immunoprecipitates. 
To address this possibility, we repeated the reprecipitation  experiment  using 
several  modifications  in  the  experimental  protocol  that  we anticipated  would 1924  Ia-ASSOCIATED  CSPG  CORE  PROTEIN  IS  INVARIANT  CHAIN 
FIGURE 4.  [aSS]sulfate-labeled CSPG  can  be reprecipitated with anti-invariant chain anti- 
body. Anti-l-A and anti-Ii immunoprecipitates were prepared from [aSS]sulfate-labeled B 10.A 
spleen  ceils,  combined,  and  fractionated on  DEAE-Sephacel  under dissociative conditions. 
Equal aliquots of the DEAE-Sephacel eluate were incubated with a control anti-I-A  d antibody 
(2), anti-I-A  k (3) or anti-Ii (4). Antigen antibody complexes were isolated with SaCI or RARIg- 
SaCI.  The  material  remaining in  the supernatants of the anti-l-A  d immunoprecipitate was 
retested with the control rat antibody (5) and material remaining in the supernatant of the 
anti-l-A  k immunoprecipitate was retested with the anti-Ii antibody (6). Lane 1 shows a portion 
of the unfractionated combined [aSS]sulfate-labeled immunoprecipitates. 
decrease or eliminate conventional invariant chain in the CSPG preparations.  In 
addition,  we prepared  samples  labeled with  [~SS]methionine  rather  than  [~S]- 
sulfate so that  presence of the Mr  31  K  invariant  chain  glycoprotein could be 
directly monitored throughout  the purification  procedure.  The CSPG was iso- 
lated from [~5S]methionine-labeled spleen cells by immunoprecipitation with anti° 
I-A  k or anti-Ii antibodies, and was eluted from the SaCI pellets, as before, with 
dissociative DEAE starting buffer. The CSPG was bound to DEAE-Sephacel and 
the resin  was extensively washed with 0.2 M  NaCI in 8  M urea.  The CSPG was 
eluted with 0.8  M  NaC1  in  8  M  urea and, after dilution  of the NaCI to 0.2  M, 
the  procedure  was  repeated.  This  two-cycle  ion  exchange  chromatography 
protocol resulted in a CSPG preparation free of invariant chain (see below). Half 
of each CSPG preparation  was then treated with chondroitinase ABC to release 
the glycosaminoglycan and yield the core protein.  The samples were pretreated 
with SaCI, and aliquots of each sample were reacted with either a control antibody 
or  the  antibody  originally  used  to  isolate  the  CSPG.  The  antibody-antigen 
complexes were isolated with SaCI or RARIG-SaCI and the immunoprecipitated 
material  was analyzed  by SDS-10%  PAGE.  The results of this experiment are 
shown  in  Fig.  5  and  a  quantitative  determination  of the  radioactivity  in  the 
immunoprecipitates  is given in Table I. 
SDS-PAGE analysis of the  0.8  M  NaCI  eluates  from  the  ion exchange  resin SANT  ET  AL.  1925 
FIGURE 5.  Isolation of the twice-purified  CSPG derived from B10.BR spleen cells with anti- 
invariant  chain mAb. [35S]methionine-laheled CSPG was prepared from anti-I-A (A) and anti- 
li  (B)  immunoprecipitates.  The  CSPG  preparations  eluted  from  the  DEAE-Sephacel  was 
reapplied to and eluted from fresh DEAE-Sephacel.  The twice-purified  CSPG preparations 
were divided  in  half and either  digested  with  chondroitinase  ABC (lanes  9-12) or mock 
digested  (5-8). Aliquots of the preparations were retested for immunoreactivity  with anti-l-A 
or anti-invariant chain antibodies.  Lanes 6-8 and 10-12 in A correspond to samples A-C and 
D-F in Table 1. Lanes 6-8 and 10-12 in B correspond to samples G-I and J-L in Table I. 
Lanes 5 and 9 correspond to the samples used for the secondary immunoprecipitations.  Lanes 
I-3 represent anti-LA  d, anti-I-A  k, and anti-li unfractionated immunoprecipitates,  respectively. 
Lane 4 represents a control unfractionated [SH]leucine-labeled anti-LA immunoprecipitate. 
(Fig.  5,  lanes  5-12) indicates  that  the  modifications  in  the  experimental  proce- 
dure  were sufficient to remove all  detectable  Mr 31  K  invariant  chain  from the 
CSPG  preparations.  When  the  CSPG  preparation  from  each  sample  was  incu- 
bated  with  SaCI  alone,  25-30%  of the  radioactivity  was absorbed  to  the  SaCI 
(Fig.  5,  A  and B,  lanes  2  and  6,  and  Table  I).  After  samples  had  been  treated 
once  with  SaCI,  subsequent  nonspecific  binding  was  negligible  and  specific 
reactivity with the antibodies  could be more rigorously evaluated.  In the immu- 
noprecipitates  prepared  from the  I-A sample (Fig.  5 A and Table I), virtually no 1926  Ia-ASSOCIATED  CSPG  CORE  PROTEIN  IS  INVARIANT  CHAIN 
TABLE  I 
Sequential Passage of the CSPG on DEAE-Sephacel before Secondary 
Immunoprecipitation 
First  Chondro-  Second  cpm in elute of 
immuno-  Sample  itinase  antibody  immuno- 
precipitate  treatment  precipitate 
I-A  A  -  SaCI*  6760 
B  -  I-A d  105 
C  --  I-A  k  165 
D  +  SaCI*  3360 
E  +  LA  d  225 
F  +  I-A  k  150 
G  -  SaCI*  6225 
H  -  PC  90 
I  -  Ii  14,610 
J  +  SaCI*  6765 
K  +  PC  165 
L  +  li  13,185 
[aSSlMethionine-labeled  CSPG  was prepared  from anti-I-A  and anti-Ii 
immunoprecipitates derived from B 10.BR spleen cells. The CSPG prep- 
arations eluted from DEAE-Sephacel were reapplied to and eluted from 
fresh DEAE-Sephacel as described in Results. The doubly purified CSPG 
preparations  were  digested  with  chondroitinase  ABC  (+)  or  left  un- 
treated  (-)  and  then  were  retested  with  antibodies  as  described  in 
Materials and Methods. PC, phosphorylcholine. 
* SaCI pretreatment pellets. 
radioactivity was isolated with  the control  anti-I-A a (lanes 6-8)  or the  specific 
anti-I-A k reagents (lanes 10-12).  In the immunoprecipitates prepared from the 
Ii sample (Fig.  5B), there was no radioactive material  isolated with the control 
rat  antibody  (Fig.  5B,  lanes  7  and  11). In  contrast,  the  anti-invariant  chain 
antibody precipitated large quantities of the CSPG and its Mr 38 K core protein 
in the total absence of detectable conventional invariant chain (Fig.  5B, lanes 8 
and 12, and Table I). Reprecipitation of the Mr 28 K core protein did not occur. 
These  results demonstrate  that  the  In-1  antibody can react directly with  both 
the intact CSPG and the chondroitinase-digested Mr 38 K core protein. 
To  confirm  the  specificity  of  this  reaction,  supernatants  of  the  anti-I-A k 
immunoprecipitates shown in Fig. 5A, lanes 7 and  11 were each divided in half 
and  retested  for  reaction  with  control  antiphosphorylcholine  mAb and  anti-Ii 
mAb.  The  resulting  immunoprecipitates  were  analyzed  by  SDS-PAGE.  The 
control antibody gave no reaction (Fig.  6,  lanes 2 and 5) but the CSPG and its 
core protein  were again  isolated by the anti-invariant  chain  antibody  (Fig.  6, 
lanes 3 and 6). These results demonstrate the specificity of the reaction of anti- 
Ii with the CSPG and its core protein. 
A control experiment (Fig. 7) demonstrates that lack of reactivity of the CSPG 
with the I-Ak-specific antibody was not due to denaturation  of the antigenic site 
recognized  by the  antibody.  The  stability  of the  site  on  I-Ae  k recognized  by 
10.2.16  has been  noted previously (18).  In  this experiment,  the  effect of 8  M 
urea on  the antigenic  site recognized  by the anti-I-A  and  anti-invariant  chain SANT  ET  AL.  1927 
FIGURE 6.  Specificity of the reaction of anti-invariant chain antibody with the CSPG and its 
core protein. Supernatants of the I-A  k immunoprecipitates derived from the CSPG preparation 
(Fig. 7A, lane 7) on the core protein preparation (Fig. 7A, lane 11) were each divided in half 
and tested with either control antiphosphorylcholine (lanes 2 and 5) or anti-Ii (3 and 6) mAb. 
Lanes 1 and 4 show the CSPG and core protein, respectively. 
FIGURE 7.  Reactivity with anti-l-A and anti-Ii antibodies is maintained after urea treatment. 
[35S]Methionine-labeled 10-2.16 (lanes I-3)- or In-1 (4-6)-immunoprecipitated material was 
eluted in urea for 16 h and then fractionated on DEAE-Sephacel. The unbound fractions were 
dialyzed against phosphate-buffered saline containing 0.1% Triton X-100. Proteins from one 
aliquot of each sample were  precipitated with  3  vol ethanol (lanes 2  and 5),  and an equal 
aliquot was reprecipitated with the antibody originally used for immunoprecipitation (3 and 
6). Shown in lanes 1 and 4 are unfractionated 10-2.16 and In-1  immunoprecipitates, respec- 
tively. 
reagents was evaluated by reprecipitating  [~SS]methionine-labeled glycoproteins 
collected  after  dissociative  ion  exchange  chromatography  on  DEAE-Sephacel. 
The  unbound  fractions  containing  ~,  /3,  and  Ii  glycoproteins  were  dialyzed 
extensively to remove urea, and then reacted with anti-I-A (Fig. 7, lanes 1-3) or 
anti-Ii (lanes 4-6) antibodies.  The resulting precipitates  were analyzed by SDS- 
PAGE. These analyses indicate that both the I-A  s chain and the invariant chain 
retained immunoreactivity  with their respective antibodies despite denaturation 
in urea. 
The  V8  peptide  analysis  and  immunoprecipitation  data  indicated  that  the 1928  la-ASSOC1ATED  CSPG  CORE  PROTEIN  IS  INVARIANT CHAIN 
I00 
~  .//"  [  I~ 
L ............  ~  ~  !i  ® 
ii~  0  ~  !  "  -::::  3  E 
7OOr  ~  i  {  i~il  l°°  : 
L  '  '-  '  .......  I  "  7" 
c  ~  ~  ~  ~:  :  :  :~!~  ?  :  ,"  O0  ' 
o  3oo  11 
,~  iI  1 
'  ~6o  '  26o  '  36o  '  46o  '  560 
FRACTION  NUMBER 
FIGURE 8.  Comparative  tryptic  peptide  map  of CSPG  core  protein  and  invariant  chain. 
[sSS]methionine-labeled CSPG core protein and [3H]methionine-labeled conventional invariant 
chain were isolated, combined, and digested with trypsin. The tryptic peptides were chromat- 
ographed on a  C-18 reverse phase HPLC column using a gradient of 0-50% acetonitrile in 
0.1% TFA. (.-.) [ssS]Methionine-labeled CSPG core protein peptides; (  ) [3H]methionine- 
labeled invariant chain peptide;  (- --)  acetonitrile gradient.  Arrows show peptides that do 
not coelute. 
CSPG core protein and invariant chain were structurally similar and antigenically 
related.  To  confirm  the  structural  identity  of the  core protein  and  invariant 
chain,  double-label  tryptic  peptide  mapping  was  performed.  [35S]methionine- 
labeled CSPG was immunoprecipitated with anti-Ii and purified by two cycles of 
binding to DEAE-Sephacel.  The CSPG eluted from the second batch of DEAE- 
Sephacel  was  treated  with  chondroitinase  to  remove  the  glycosaminoglycan, 
yielding  [35S]methionine-labeled  core protein.  [3H]methionine-labeled  conven- 
tional Mr 31  K invariant chain was immunoprecipitated with anti-Ii and isolated 
directly by preparative  SDS-11% PAGE. Equal counts per minute of the [35S]- 
methionine-labeled core protein and the [3H]methionine-labeled invariant chain 
were  combined  and  digested  with  trypsin  as  previously  described  (17).  The 
resulting  tryptic peptides were then  separated on a  C-18 reverse phase  HPLC 
column, using a gradient of 0-50% acetonitrile in 0.1% TFA. The elution profile 
of the peptides is shown in Fig. 8. From the sequence of the murine and human 
invariant chains (19-21), between 9 and  11  methionine-labeled tryptic peptides 
would have been expected if trypsin digestion had been complete.  11 major and 
15  minor  peptides are  in  fact  seen  for each  chain.  The  larger  than  expected 
number of peptides is attributable to partial digestion. 42 of the 52 total peptides 
coeluted, indicating  the nearly complete structural  identity between the CSPG 
core protein and invariant chain.  Five peptides from each of the proteins do not 
coelute (arrows). Because these peptides were derived from molecules that were 
not treated with neuraminidase,  they may bear sialic acid residues on N-linked 
or  O-linked  oligosaccharides.  The  presence  of varying  numbers  of sialic  acid 
residues on a glycopeptide of the same amino acid sequence can produce HPLC 
peaks of varying mobility and  could account for the lack of coelution of these 
peptides.  The sialic acid residues are more likely to be on the peptides derived 
from the CSPG core protein and, thus, these peptides would be expected to elute 
earlier from a reverse phase column than their nonsialated counterparts derived 
from the invariant  chain.  Earlier elution  of the noncoeluting peptides derived SANT  ET  AL.  1929 
from the CSPG core protein was in fact the observed result. Another explanation 
for differences in  the  peptide  elution  patterns  is  variation  in posttranslational 
processing that causes differential tryptic cleavage or affects behavior in reverse 
phase chromatography. 
Discussion 
The studies described in this report involve the initial characterization  of the 
core protein of a  chondroitin sulfate proteoglycan (CSPG) molecule that specif- 
ically  associates  with  murine  Ia  antigens.  We  have  developed  methods  for 
biosynthetically  labeling  the  CSPG  with  amino  acids  and  for  purifying  the 
molecule to be virtually free of other spleen cell components.  The purification 
procedure that proved most successful involved a combination of immunoprecip- 
itation and dissociative anion exchange chromatography.  The purified,  labeled 
CSPG was treated with  glycosidases to degrade the glycosaminoglycan compo- 
nent and release it from the core protein, so that structural analyses of the core 
protein could be performed. 
One-dimensional  SDS-PAGE  indicates  that  the  core  protein  of the  CSPG 
migrates  as a  doublet of Mr  38  and  28  K.  Comparative  V8 peptide  mapping 
studies  indicate  that  the  28  K  molecule  is  structurally  related  to  the  38  K 
molecule.  The  V8  peptide  mapping  studies  also show  that  the Mr  38  K  core 
protein yielded a  peptide pattern  similar to that  generated  by V8 digestion  of 
invariant  chain,  and  suggested that  the  two molecules are structurally related. 
This latter finding raised the intriguing  possibility that the core protein of the 
CSPG might in fact be invariant chain.  To investigate this possibility, we evalu- 
ated whether the CSPG or its core protein reacts directly with an anti-invariant 
chain  mAb. The  reprecipitation  data shown in  Figs.  4  and  5  indicate that  the 
monoclonai anti-Ii reagent directly bound the intact CSPG and the M~ 38 K core 
protein but not the 28 K core protein. Tryptic peptide comparison of the Mr 38 
K  core  protein  and  conventional  invariant  chain  convincingly  establish  the 
structural  relatedness  of the  two proteins.  Furthermore,  in  experiments  to be 
presented in a separate report (A. J. Sant, J. Miller, and R. Germain, manuscript 
in preparation)  we have documented that  transfection  of the murine  invariant 
chain gene into a fibroblastoid cell line leads to expression of the immunoreactive 
form of the CSPG. Together, our experiments indicate that the CSPG molecule 
that  specifically associates with  Ia antigens  is an  alternately  processed form of 
invariant chain. 
A set of invariant chain proteins has been previously demonstrated in mouse 
and human  cells, and it is therefore of interest to consider which of these may 
serve as a substrate for addition of the glycosaminoglycan. It is established (22) 
that, although only a single invariant chain gene is present in the murine genome, 
there are two transcripts from the gene that give rise to Mr 31 and 41 K proteins, 
both of which bear the epitope recognized by the In-1  monoclonal antibody. In 
the human system, it has been suggested (21) that multiple transcripts exist and 
that these could give rise to the other Ii-related proteins routinely coprecipitated 
with class II molecules. In the murine system, the anti-Ii reagent also coprecipi- 
tates smaller polypeptides, including one of M~ ~25  K  (p25), which appears to 
bear some structural  relatedness  to the  31  K  glycoprotein (22, 23).  It has not 1930  Ia-ASSOCIATED  CSPG  CORE  PROTEIN  IS  INVARIANT  CHAIN 
been  firmly established  whether  these smaller  molecules arise  from  truncated 
transcripts  or are  generated  by cleavage of a  larger  protein  molecule (p31  or 
p41). Although some Western blotting experiments have been performed, reac- 
tivity of the anti-Ii  reagent with p25 is weak at best, and it is not clear whether 
the p25  no longer  bears the  In-1  epitope or if the  In-1  epitope is simply less 
stable in the smaller molecule. 
The  CSPG core proteins  that  we have recovered have molecular weights of 
~38 and  28  K.  Based on  their  residual  size heterogeneity,  it is  likely that  the 
core proteins  retain  variable amounts  of sugar  residues.  The  known  cleavage 
capabilities of chondroitinase indicate that these core proteins retain at least the 
internal  trisaccharide,  xylose-galactose-galactose. Therefore,  the core polypep- 
tides are actually somewhat smaller than  38 or 28 K. The most likely candidates 
for CSPG precursors among the Ii family of proteins would thus appear to be 
the  M,  31  K  protein,  which  carries  the  In-1  epitope  strongly,  and  the  25  K 
protein,  on  which  the  epitope  is  represented  weakly,  if at  all.  Our  data  are 
consistent with this conclusion but do not directly show it. 
The  implications  of our  findings  should  be  considered  in  the  context  of 
previous observations  regarding  the association of invariant  chain  with  the  Ia 
glycoproteins. Sung and Jones (24) and others (25, 26) have presented evidence 
indicating  that  invariant  chain  is exclusively an  intracellular  component.  This 
was recently confirmed in the human  system by Acolla et al.  (27), who demon- 
strated  that  the Mr 33  K  invariant  chain  and several related invariant  proteins 
are synthesized constitutively in an Ia-negative B celt variant, but that no proteins 
of the invariant chain family can be detected on the cell surface of the Ia-negative 
B cell variant or its Ia-positive parent.  In addition, the results of Sung and Jones 
(24) and  others  (25,  26) suggest that  invariant  chain  interacts  only transiently 
with  the  intracytoplasmic  forms  of Ia  antigens.  Pulse chase  labeling and  two- 
dimensional gel analysis performed by Machamer and Cresswell (28) support this 
hypothesis.  They found  that,  in  the  human  system,  invariant  chain  associates 
with Ia antigens at the early stages of biosynthesis as an Mr 31  K high-mannose- 
bearing glycoprotein. With maturation and transport of the 0t and/3 glycoproteins 
to the Golgi apparatus,  invariant  chain  remains associated with  the dimer and 
undergoes coordinate posttranstational modifications including processing of the 
N-linked high mannose oligosaccharides to the complex type and addition of O- 
linked  sugars  to form  "acidic" or  "processed" invariant  chain.  Because neither 
that Mr 31  K  high  mannose form nor the  35  K acidic form of invariant  chain 
was detected on the plasma membrane with Ia antigens, their results (28) indicate 
that,  at some stage between these late processing steps and  plasma  membrane 
expression of the Ia heterodimer,  invariant chain dissociates from the Ia a  and 
fl dimer. Similar results have been found recently in the murine system (29), with 
the  exception  that  the  processing  of invariant  chain  was  thought  not  to  be 
completed until after it was dissociated from the ol, t3 dimer. 
In other experiments (8), we presented evidence indicating  that  the CSPG is 
associated with Ia antigens expressed at the plasma membrane, as well as with an 
intraceIlular pool of these glycoproteins. The observation that  the core protein 
of the CSPG is indeed invariant chain leads to speculation that the apparent loss 
of the invariant  chain  with  maturation  and plasma membrane  expression of Ia SANT  ET  AL.  1931 
antigens  may not reflect an actual  dissociation  of this  component  from the  Ia 
heterodimer but rather a  biosynthetic conversion of the Mr 31  or 35 K species 
to the 46-70  K proteoglycan molecule.  In this form, invariant  chain would be 
cotransported with Ia antigens to the plasma membrane. 
The  finding  that  invariant  chain  can  be converted  to a  proteoglycan  form 
which is coexpressed with  Ia at the plasma membrane  forces a  reevaluation  of 
the  potential  functions  of this  molecule  in  the  biology of Ia  antigens.  These 
potential  functions  can  be  organized  into  three  main,  nonmutually  exclusive 
categories:  biosynthesis/targeting,  participation  in  Ia-mediated cellular interac- 
tions, and turnover/recycling.  First,  invariant chain/CSPG may function in the 
biosynthesis of Ia by expediting transport of Ia through  the intracellular organ- 
elles responsible for posttranlational  processing, or by targeting Ia to the plasma 
membrane. Previous studies (24, 28, 29) indicating that invariant chain associates 
with  Ia  glycoproteins early in  biosynthesis en  route to the plasma  membrane, 
and then dissociates from the heterodimer, limited the role of invariant chain to 
events occuring before expression of Ia at the cell surface. Our finding that the 
CSPG is associated with cell surface Ia suggests that, if invariant chain is indeed 
responsible  for final  transport  of Ia  to the plasma  membrane,  it  is  the  CSPG 
form of invariant chain that mediates this event.  In this form, the CSPG might 
target Ia to specialized regions of the plasma membrane. 
Moreover, the association of CSPG with cell surface Ia establishes the  latter 
two categories of potential functions as viable alternatives. Thus, the CSPG could 
be an  integral  part of the  Ia-oligomer complex on the plasma membrane,  and 
participate directly in Ia-mediated cellular interactions or facilitate such interac- 
tions. Alternatively, the CSPG might regulate or direct turnover or recycling of 
Ia molecules. With regard to recycling, for example, if recycling of Ia is necessary 
for antigen  processing,  the  CSPG could potentially  function  to protect  the  Ia 
molecules from intracellular degradation. 
It is  interesting  to note  that  invariant  chain  shares  some unusual  structural 
features with the transferrin receptor, a molecule with a clearly defined function. 
Based  on  sequence  information  derived  from  cDNA  clones,  the  mouse  and 
human  invariant  chains  (19-21) and  transferrin  receptor proteins (30,  31) are 
synthesized  without  an  amino-terminal  signal  sequence;  in  contrast  to  most 
membrane  proteins,  these  proteins  appear  to  be  oriented  with  their  amino 
termini  on the cytoplasmic side of the membrane.  In addition,  both transferrin 
receptor  (32)  and  invariant  chain  (S.  Simonis  and  S.  E.  Cullen,  manuscript 
submitted) can be covalently fatty acylated. Finally, just as invariant chain can be 
alternately  processed to a  proteoglycan  form,  it  has  recently been found  (33) 
that  the  transferrin  receptor can  be alternately  processed to a  heparin  sulfate 
proteoglycan form  which  remains  reactive  with anti-transferrin  receptor anti- 
body and can still  bind transferrin.  The involvement of transferrin  receptor in 
the intracellular  transport  of transferrin,  and the general  structural  similarities 
between transferrin  receptor  and  invariant  chain,  lead  to  speculation  that  an 
analogous intracellular  transport function exists for invariant chain. 
An unresolved issue is whether there is an obligatory role of invariant chain/ 
CSPG in  the  normal  biology of Ia glycoproteins.  To evaluate the necessity of 
invariant  chain  in  normal  Ia  maturation  and  plasma  membrane  expression,  it 1932  la-ASSOC1ATED  CSPG CORE PROTEIN  IS  INVAR1ANT CHAIN 
should be possible to transfect cells that are totally deficient in invariant chain 
with a  and 3 chain genes and determine if the corresponding gene products are 
expressed at the plasma membrane.  In addition, comparison of cells transfected 
with  o~, /3, and  invariant chain  genes with  those  transfected with only a  and  3 
chain  genes,  or  a  comparison  of invariant  chain  nonexpressor  mutants  with 
parental  cells,  should  allow  an  assessment  of the  role  of the  invariant  chain/ 
CSPG  in  Ia  processing  and  turnover/recycling and  in  antigen  presentation. 
Approaches such as these should resolve some of the issues raised and elucidate 
the role of the various forms of invariant chain in the biology of the Ia molecules. 
Summary 
The murine Ia-associated chondroitin sulfate proteoglycan (CSPG) was studied 
both biochemically and  immunochemically to determine the nature of its core 
protein.  Chondroitinase  ABC  or  chondroitinase  AC  treatment  of the  CSPG 
digested the chondroitin sulfate glycosaminoglycan, yielding a core protein that 
migrated with an apparent molecular weight of 38,000. Comparative V8 protease 
digestion  of the  CSPG  core  protein  and  conventional  invariant  glycoproteins 
yielded homologous peptides, indicating that the core protein and invariant chain 
were  structurally  similar.  The  purified  CSPG  and  its  core protein  were  both 
shown to react directly with the monoclonal anti-invariant chain antibody, In-1. 
Comparative tryptic peptide analysis by high performance liquid chromatography 
demonstrated coelution of the majority of the peptides from the invariant chain 
and the CSPG core protein. Collectively, these results indicate that the CSPG is 
an alternatively processed form of invariant chain. 
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